#India #Mumbai #ADC technology #Piramal Pharma #Aji Bio-Pharma

Piramal Pharma and Ajinomoto Bio-Pharma Join Forces to Advance ADC Production

In a strategic partnership that promises to innovate the field of biopharmaceuticals, Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services are set to enhance the development and manufacturing of antibody-drug conjugates (ADCs). This collaboration aims to leverage both companies' strengths, offering comprehensive solutions for clients in need of advanced ADC production technology.

A Leader in ADC Development

With over two decades of experience, Piramal Pharma Solutions is recognized globally as a frontrunner in the Contract Development and Manufacturing Organization (CDMO) sector, particularly for ADCs. Their expertise covers everything from early-phase development through to commercialization, showcasing a robust network of state-of-the-art facilities around the world.

On the other hand, Ajinomoto Bio-Pharma Services brings to the table its proprietary AJICAP™ technology, which simplifies the manufacturing of site-specific ADCs and linkers. This unique set of technologies allows for heightened efficiency and effectiveness in the drug development process, ultimately aiming for higher therapeutic efficacy and reduced toxicity in the resulting treatments.

Enhancing Client Offerings

This partnership will allow Piramal to refer clients seeking ADC manufacturing technology to Ajinomoto, while Ajinomoto will recommend Piramal as a potential CDMO for clients utilizing the AJICAP™ technology. A separate material transfer agreement (MTA) will also be established to facilitate the transfer of technology between the two companies. This agreement will empower Piramal with the knowledge, skills, and workforce necessary to produce AJICAP™-based products quickly and accurately.

Peter DeYoung, CEO of Piramal Global Pharma, expressed enthusiasm about the collaboration, stating, "We are excited to partner with Ajinomoto Bio-Pharma Services, expanding our ADC platform by providing support for the manufacturing of AJICAP™-based products. This capability will accelerate innovation and broaden access to this technology for our customers and their patients worldwide."

Similarly, Yasuyuki Otake from Ajinomoto noted that this cooperation enhances the ecosystem surrounding AJICAP™ technology, aiming to connect licensed customers with experienced ADC manufacturing partners. He emphasized the pursuit of quality programs from early development stages to full commercialization.

Innovating ADC Technologies

The combination of AJICAP™ technology with Piramal's extensive experience in ADC Good Manufacturing Practices (GMP) allows for the accelerated development of precise and effective therapies. With widespread commercial ADC manufacturing capabilities and ongoing expansions aimed at increasing capacity, Piramal is well-equipped to meet rising global demands.

An industry pioneer, Piramal has not only been the first ADC CDMO approved by the FDA but has also completed numerous batches, emphasizing its proficiency in the commercial landscape.

As these two industry leaders combine their expertise, they are positioning themselves to deliver innovative and efficient solutions in ADC production. The strategic alignment not only fosters technological advancement but also serves to provide safer and more effective treatments to patients around the globe.

About Piramal Pharma Solutions

Piramal Pharma Solutions operates through a vast global network encompassing North America, Europe, and Asia, providing a comprehensive range of services that span drug research, process development, and clinical supply through to commercial delivery of APIs and finished forms. This includes specialized offerings like the manufacturing of high-potency APIs and ADCs, along with services associated with sterile filling/finalization, peptide products, and oral solid dosage forms.

About Aji Bio-Pharma Services

Ajinomoto Bio-Pharma Services, with sites in Belgium, India, Japan, and the United States, is a fully integrated CDMO dedicated to supporting both large and small molecule drug production. Their services range from preclinical to commercial quantities, ensuring high quality and service levels that meet varied client needs.

In conclusion, the partnership between Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services stands to revolutionize the ADC landscape, creating pathways for innovation and improved patient outcomes through collaborative expertise.